Compare RGNT & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNT | AIDX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 19.5M |
| IPO Year | N/A | N/A |
| Metric | RGNT | AIDX |
|---|---|---|
| Price | $2.15 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 52.2K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $1.32 |
| 52 Week High | $8.35 | $14.09 |
| Indicator | RGNT | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 24.88 | 23.72 |
| Support Level | N/A | N/A |
| Resistance Level | $3.35 | $1.66 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 14.53 | 14.61 |
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.